Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trails for cnacer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in San Diego, CA on December 10-13, 2011.
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...